Cardiopulmonary

Oncology

CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

February 3, 2025

Belgium

Cardiopulmonary

Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization

April 8, 2024

United States

Cardiopulmonary

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24

Clinical and real-world evidence presentations highlight how the Company is transforming care for patients who are fighting some of the most common and devastating cardiovascular diseases

April 4, 2024

United States

Cardiopulmonary

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

March 22, 2024

United States

Cardiopulmonary

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)

November 14, 2023

United States

Cardiopulmonary

Janssen Announces Update to Phase 3 MACiTEPH Study Evaluating Macitentan 75mg in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

September 6, 2023

United States

Cardiopulmonary

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

June 26, 2023

Belgium

Cardiopulmonary

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

May 30, 2023

United States

Cardiopulmonary

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

May 25, 2023

United States

Cardiopulmonary

Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)

March 6, 2023

United States

Cardiopulmonary

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)

March 5, 2023

United States

Cardiopulmonary

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension

November 8, 2022

United States

Cardiopulmonary

Janssen’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations

November 4, 2022

United States

Cardiopulmonary

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)

May 23, 2022

United States

Cardiopulmonary latest news

Discover J&J

Medicines & therapies

Medical devices & technology

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

About us

You are now leaving innovativemedicine.jnj.com

Key links

Get in touch

Search Results

No Results

Recently Viewed

Cardiopulmonary latest news

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com